Dear Readers,

The increasing prevalence of diabetes mellitus (DM) is one of the biggest current public health challenges. In this issue we published an extensive article regarding the economic burden of macro- and microvascular diseases associated with DM in various Central and Eastern European countries.

In addition we are pleased to present you an updated statement on the safety of biological treatments with monoclonal antibodies and fusion proteins. This document was carefully prepared by a team of leading Polish experts in this area.

Over recent years, we have observed a rapid increase in the number of patient claims in Poland. Leśniak et al. analysed some cases from a selected law firm and highlighted some issues that potentially hinder risk management in health care entities.

We also recommend other articles regarding secondary immunodeficiencies, familial amyloid polyneuropathy treatment, reimbursement decisions made by the Polish Minister of Health regarding oncological drugs,  as well as the advantages and disadvantages of emergency access to drug technologies.

Karina Jahnz-Różyk, Editor-in-Chief

Joanna Lis, Deputy Editor-in-Chief

Monika Szkultecka-Dębek, Deputy Editor-in-Chief